NCT02653131

The Use of DPP-4 Inhibitors in Short Bowel Syndrome

The Use of Dipeptidyl Peptidase-4 Inhibitor Influences the Absorption of Intestine in Short Bowel Syndrome

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Stanley Dudrick's Memorial Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The inhibition of Dipeptidyl peptidase-4 should increase the concentration of glucagone-like peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of the intestine.

Detailed description

The only effective (to some extend drug) in short bowel syndrome is Glucacone-like peptide 4. Its price is, however, to high to really change the treatment strategy for intestinal failure. The Dipeptidyl peptidase-4 inhibitor, which a drug which is commonly used in the treatment of diabetes mellitus type II, should increase the concentration of glucagone-like peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of the intestine.

Conditions

• Short Bowel Syndrome

Interventions

Type	Name	Description
DRUG	Dipeptidyl peptidase-4 inhibitor

Timeline

• Start date: 2016-01-01
• Primary completion: 2020-04-01
• Completion: 2020-04-01
• First posted: 2016-01-12
• Last updated: 2020-04-15

Locations

1 site across 1 country: Poland